(Q40225104)

English

Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors

scientific article published on October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

fluticasone propionate

1 reference

based on heuristic

inferred from title

author name string

Volonaki E

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Psarras S

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Xepapadaki P

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Psomali D

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gourgiotis D

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Papadopoulos NG

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Clinical & Experimental Allergy

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1268-1273

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Asthma. From bronchoconstriction to airways inflammation and remodeling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

The bronchial epithelium: translating gene and environment interactions in asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Rhinovirus infection up-regulates eotaxin and eotaxin-2 expression in bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Epithelial-mesenchymal interactions in the pathogenesis of asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Biological roles of fibroblast growth factor-2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Beta-adrenergic receptors and their regulation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Combination therapy: Synergistic suppression of virus-induced chemokines in airway epithelial cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Growth factors are released by mechanically wounded endothelial cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Impact of inhaled corticosteroids and leukotriene receptor antagonists on airway remodeling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

The role of rhinovirus in asthma exacerbations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Mechanisms of rhinovirus-induced asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Molecular interactions between glucocorticoids and long-acting beta2-agonists.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2006.02566.X

21 January 2018

Identifiers

10.1111/J.1365-2222.2006.02566.X

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40225104&oldid=1889364690"